ADNI Session of the American Academy of Neurology 2009 Annual Meeting
this $64-million initiative in a two-part series by Esther Landhuis. American Academy of Neurology: 2009 Annual
ALL NEWS
378 RESULTS
You searched Esther
Sort By:
- Most Recent
- Most Commented
- Most Relevant
Michael J. Fox Foundation Launches Big PD Biomarker Study
also collecting brain imaging, genetics, biologic, and clinical data. Read Esther Landhuis's
Gladstone Workshop: From Science to Therapeutics: The Best Way Forward
Disease. Over the coming days, read Esther Landhuis' highlights, which cover new functions for BACE,
Gladstone Workshop: Tau and Tauopathies: Pathogenic Mechanisms
with Esther Landhuis's unfolding coverage of the San Francisco conference and her now-complete coverage
Toward a High in Cannabinoid Research: News on Neuroprotective Effect
parts of Alzheimer's research, as well. Esther Shohami at Hebrew University's Medical Faculty
Paper Alert: First BACE Trial Published—New Inhibitor On Deck
lowering can be achieved by BACE1 inhibition in humans,” the authors write.—Esther Landhuis None
Paper Alert: In Vivo Human Data Shows Reduced Aβ Clearance in AD
or a combined increase in Aβ production with impaired efflux from parenchyma to CSF,” they noted.—Esther
Paper Alert: Anti-Inflammatory Blocks Aβ Deposition in AD Mice
of CNI-1493 as an AD drug.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=1865
Research Brief: Meet Drosophila ’s Stinging Sister, Nasonia
related news story).—Esther Landhuis. None http://www.alzforum.org/new/detail.asp?id=2335 Research Models
BACE Inhibitors Hitch Ride into Endosomes via Membrane Anchor
intraventrically can produce effects comparable to direct injections into the hippocampus.—Esther Landhuis Esther
HAI Seattle: Not Just Amyloid, Not Just PIB
2009).—Esther Landhuis. This is Part 3 of a four-part series. See Part 1, Part 2, and Part 4. All attendees
Guardian Amyloid? Aβ Hexamers Help Multiple Sclerosis Mouse Model
2013). —Esther Landhuis Q&A With Lawrence Steinman. Questions by Esther Landhuis. Q: What motivated
Medical Foods—Fallback Option for Elusive AD Drug Status?
twice—with news of elevated AD risk, and without another potential treatment option.—Esther Landhuis.
Will Tau Drug Show Its True Colors in Phase 3 Trials?
in 2002 with Kwang Meng Seng, a physician and venture capitalist.—Esther Landhuis. Q&A With Claude
Q&A With Merck’s Johan Luthman
story; EPOCH). Q&A With Johan Luthman. Questions by Esther Landhuis. Q: ClinicalTrials.gov says